Edition:
United Kingdom

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

1.00USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,409
52-wk High
$3.70
52-wk Low
$0.80

Summary

Name Age Since Current Position

Julian Aleksov

52 2017 Executive Chairman of the Board

Mikael Asp

55 2015 Chief Executive Officer

Anders Blom

48 2017 Acting Chief Financial Officer, Executive Vice President

Magdalena Berg

Head of Accounting

Dzianis Babrou

Head of Product Development

John Cosby

55 Head of Regulatory Affairs

Nina Heldring

Head of Clinical Development

Henrik Ronnberg

Chief Medical Officer Animal Health

Bo Cederstrand

78 2011 Director

Per Lango

2017 Director

Lars Bergkvist

53 2015 Independent Director

Alexander Kotsinas

50 2013 Independent Director

Biographies

Name Description

Julian Aleksov

Mr. Julian Aleksov has been Executive Chairman of the Board of Oasmia Pharmaceutical AB since February 28, 2017. He has previously been Executive Vice Chairman of the Board of the Company since November 21, 2016. Before that, he has been Executive Chairman of the Board of Oasmia Pharmaceutical AB since May 29, 2015. He has previously served as Chief Executive Officer (CEO) of Oasmia Pharmaceutical AB, and he has been Member of the Company’s Board of Directors since 1999. He is one of the Founders of the Company. He has experience in the coordination of research projects and strategic development of global intellectual property. He currently serves as Chairman of the Board of Directors of Oasmia Incentive AB and Qdoxx Pharma AB. He is Economist.

Mikael Asp

Mr. Mikael Asp has been Chief Executive Officer at Oasmia Pharmaceutical AB since May 29, 2015. He has previously been Head of Quality Assurance of Oasmia Pharmaceutical AB since 2013. He holds a Master of Science degree in Chemical Engineering and has 25 years of experience from several companies within international pharmaceutical industry in research and development, production, quality assurance and as Qualified Person (QP). He is Member of the Board of Oasmia Incentive AB.

Anders Blom

Mr. Anders Blom has been appointed Executive Vice President of Oasmia Pharmaceutical AB, effective as of October 1, 2014 and he has been Acting Chief Financial Officer of the Company since October 4, 2017. He has more than 15 years of experience from international strategic business development and finance at Q-Med, Galderma and Pharmacia. He has a degree in Business Administration from Uppsala University. He has recently been CEO of Nexttobe AB.

Magdalena Berg

Dzianis Babrou

John Cosby

Mr. John Cosby serves as Head of Regulatory Affairs at Oasmia Pharmaceutical AB. He joined the Company in 2006. He holds Bachelor of Science degree in Chemistry from the University of Maryland, the United States. He has many years of experience from several companies within international life science, with responsibility for regulatory affairs and product development.

Nina Heldring

Henrik Ronnberg

Bo Cederstrand

Mr. Bo Cederstrand has served as Member of the Board of Directors at Oasmia Pharmaceutical AB since February 8, 2011. He was Chairman of the Company's Board of Directors from 2000 until February 8, 2011. He has about 40 years' experience as Chief Executive Officer and Partner at a number of small and mid-sized businesses, mainly within trade. He also has experience in international trade and production. He has been active within trade associations. He is Deputy Member of the Board of Fruges AB and former Member of the Board of Arken Hemdjurshallarna.

Per Lango

Lars Bergkvist

Mr. Lars Bergkvist has served as Independent Member of the Board of Directors of Oasmia Pharmaceutical AB since May 28, 2015. Lars is a Business Administration graduate and has previously worked in the management of a number of successful companies. Hans has been the CEO of Arken Zoo and Hidden Dinosaur, among others. He also has many years of experience of working as board member and chairman in FDT AB, Master Design AB and Swedish Franchise, among others.

Alexander Kotsinas

Mr. Alexander Kotsinas has served as Independent Member of the Board of Directors of Oasmia Pharmaceutical AB since September 30, 2013. He has served as Vice President and Chief Financial Officer at Q-Med AB from February 2008 until 2011. Mr. Kotsinas has also served as Chief Financial Officer at Life Europe AB and the mobile provider 3. He served as a Vice President at Investor AB and has also worked at Ericsson. He holds a Master of Science degree from the Royal Institute of Technology (Kungliga Tekniska Hogskolan – KTH) in Applied Physics and a Bachelor of Science degree from Handelshogskolan in Stockholm.

Basic Compensation